Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
Fox
Robert J
RJ
D001921:Brain / Q000187:drug effects / Q000473:pathology; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D007212:Indolizines; D011720:Pyrazoles
D018696:Neuroprotective Agents; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles